Workflow
武汉东湖高新集团股份有限公司 关于为全资子公司武汉东湖高新医药投资有限公司提供担保的公告

Core Viewpoint - The company has signed a guarantee contract with Agricultural Bank of China for a loan of RMB 600 million for its wholly-owned subsidiary, Wuhan Donghu Gaoxin Pharmaceutical Investment Co., Ltd, indicating a strategic move to support its subsidiary's financing needs [2][4]. Group 1: Guarantee Overview - The company will provide a guarantee of RMB 600 million for the loan applied by its subsidiary, with no outstanding balance prior to this guarantee [2][3]. - As of September 10, 2025, the total actual guarantee amount provided by the company to its wholly-owned and controlling subsidiaries is RMB 1.267 billion, while guarantees to associated companies amount to RMB 1.038 million [3][12]. Group 2: Internal Decision-Making Process - The company's board of directors approved the 2025 annual guarantee plan, allowing for a total guarantee amount of up to RMB 6.125 billion for its subsidiaries, with specific limits based on their debt-to-asset ratios [4][10]. - The shareholders' meeting on June 5, 2025, ratified the 2025 annual guarantee plan [4]. Group 3: Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary to alleviate financial pressure for project construction and to meet operational needs [9]. - The guarantee does not constitute a related party transaction and is expected to have no adverse impact on the company's interests or operational independence [4][9]. Group 4: Board's Opinion - The board believes that the subsidiaries have repayment capabilities and that the guarantee will not harm the company's interests, thus supporting the decision to proceed with the guarantee [10].